SCHEMBL4023015

SCHEMBL4023015

COc1ccc(-c2nc(=O)c3ccccc3o2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.63
MAPT P10636 6/20 0.63
NPC1 O15118 6/20 0.63
RAB9A P51151 6/20 0.63
KDM4E B2RXH2 6/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
LMNA P02545 2/20 0.63
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
MAPK1 P28482 1/20 0.61
MAOB P27338 3/20 0.57
HPGD P15428 3/20 0.57
ABCG2 Q9UNQ0 3/20 0.57
CYP3A4 P08684 2/20 0.57
HSD17B10 Q99714 2/20 0.57
TNKS O95271 1/20 0.57
TP53 P04637 1/20 0.57
GLA P06280 1/20 0.57
THRB P10828 1/20 0.57
KCNA5 P22460 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL812662 0.87 NPC1 (0.53) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL7795159 0.87 MAOB (0.58) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL12228491 0.84 CYP19A1 (0.60) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL9616651 0.84 HPGD (0.66) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL17254766 0.84 HSD17B10 (0.49) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL17254793 0.83 NPC1 (0.52) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL5307439 0.83 NPC1 (0.60) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL4028915 0.82 ELANE (0.54) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL30025603 0.82 ELANE (0.58) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL4029088 0.82 ELANE (0.58) ALDH1A1MAPTNPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070148185-A1 Novel therapeutic target for protozoal diseases VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY 2007-06-28 US claimed
WO-2007047579-A2 A NOVEL THERAPEUTIC TARGET FOR PROTOZOAL DISEASES VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2007-04-26 WO claimed
EP-1213283-B1 Biphenyl-substituted triazines as light stabilisers CIBA HOLDING INC (CH) 2009-04-29 EP disclosed
US-6919454-B2 Biphenyl-substituted triazines CIBA SPECIALTY CHEMICALS CORP. (US) 2005-07-19 US disclosed
US-20050019281-A1 Biphenyl-substituted triazines FLETCHER IAN JOHN (CH) 2005-01-27 US disclosed
US-6841670-B2 High thermal stability, are used as stabilizers for organic polymers to counter damage thereto caused by light, oxygen and heat, as light stabilizers for textile fiber materials and as sunscreens for the human skin. CIBA SPECIALTY CHEMICALS CORPORATION (US) 2005-01-11 US disclosed
US-20030045444-A1 Biphenyl-substituted triazines FLETCHER IAN JOHN (CH) 2003-03-06 US disclosed
EP-0863906-B1 HETEROCYCLIC DIOXETHANE SUBSTRATES, PROCESS FOR THEIR PREPARATION AND THEIR USE ROCHE DIAGNOSTICS GMBH (DE) 2003-02-12 EP disclosed
EP-0899266-B1 Process for the production of benzoxazinones CIBA SC HOLDING AG (CH) 2003-01-15 EP disclosed
US-6468958-B2 LIGHT, OXYGEN AND HEAT RESISTANCE CIBA SPECIALTY CHEMICALS CORPORATION 2002-10-22 US disclosed
EP-1213283-A2 Biphenyl-substituted triazines as light stabilisers Ciba SC Holding AG (CH) 2002-06-12 EP disclosed
US-6255483-B1 USEFUL AS LIGHT STABILIZERS FOR TEXTILE FIBER MATERIALS AND SUNSCREENS FOR HUMAN SKIN CIBA SPECIALTY CHEMICALS CORPORATION 2001-07-03 US disclosed
US-6107036-A Heterocyclic dioxethane substrates, process for their preparation and their use ROCHE DIAGNOSTICS GMBH (DE) 2000-08-22 US disclosed
US-6040443-A Process for the production of benzoxazinones CIBA SPECIALTY CHEMICALS CORPORATION (US) 2000-03-21 US disclosed
EP-0899266-A1 Process for the production of benzoxazinones Ciba SC Holding AG (CH) 1999-03-03 EP disclosed
EP-0863906-A2 HETEROCYCLIC DIOXETHANE SUBSTRATES, PROCESS FOR THEIR PREPARATION AND THEIR USE Roche Diagnostics GmbH (DE) 1998-09-16 EP disclosed
EP-0815089-A1 BIPHENYL-SUBSTITUTED TRIAZINES AS LIGHT STABILIZER Ciba SC Holding AG (CH) 1998-01-07 EP disclosed
WO-1997014696-A2 HETEROCYCLIC DIOXETHANE SUBSTRATES, PROCESS FOR THEIR PREPARATION AND THEIR USE BOEHRINGER MANNHEIM GMBH (DE) 1997-04-24 WO disclosed
WO-1996028431-A1 BIPHENYL-SUBSTITUTED TRIAZINES AS LIGHT STABILIZER CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1996-09-19 WO disclosed
US-3957780-A ULTRAVIOLET LIGHT STABILIZERS, PLASTICS HOECHST AKTIENGESELLSCHAFT (DT) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050019281-A1 Biphenyl-substituted triazines TYR, AHR, CUTA ALDH1A1 402/4885MAPT 60/4885NPC1 4339/4885
US-20030045444-A1 Biphenyl-substituted triazines TYR, CYP1B1, NFE2L2 ALDH1A1 109/4885MAPT 111/4885NPC1 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.